Your First Month on GLP-1

During the first week, most patients notice a gradual reduction in appetite within 1-3 days of their first injection. Some patients experience mild gastrointestinal symptoms such as nausea, bloating, or mild stomach discomfort, especially as the body adjusts to the medication. These symptoms are typically transient and subside as your dose is gradually increased. Your licensed provider will start you on a low dose (typically 0.25mg weekly) to minimize side effects and monitor your response before advancing.

Weight loss during the first month varies significantly between individuals. Most patients lose 2-5 pounds in the first 4 weeks, though some may experience more rapid initial changes. The first month is primarily a titration phase where your provider adjusts your dose to find your optimal therapeutic level. Meaningful, sustained weight loss typically becomes more apparent in months 2-4 as you reach higher therapeutic doses. Individual results vary and are not guaranteed.

Common side effects in the first month include nausea (the most common), mild stomach discomfort or cramping, occasional constipation or diarrhea, and fatigue. These are usually mild to moderate and tend to improve as your body adjusts. Your provider will start at a low dose and increase gradually to minimize these effects. If side effects are severe or persistent, contact your provider immediately. Always report any unusual symptoms.

While GLP-1 medications reduce appetite naturally, making intentional dietary changes can optimize your results and minimize side effects. Your provider may recommend: smaller, more frequent meals; increased protein intake (1.2-1.6g per kg body weight); limiting high-fat foods which can worsen nausea; staying well-hydrated; and avoiding alcohol which can interact with the medication. Focus on nutrient-dense foods to support your body during the adjustment period.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two metabolic pathways simultaneously, while semaglutide is a single GLP-1 receptor agonist. For beginners, tirzepatide may produce more pronounced appetite suppression and greater average weight loss in clinical trials with FDA-approved formulations. However, some patients report more side effects with tirzepatide, particularly at higher doses. Semaglutide may be preferred for patients with a history of medication sensitivity. Your provider will recommend the appropriate medication based on your health profile.

You may notice appetite reduction within the first week. By week 4, you should have a sense of whether the medication is affecting your hunger and eating patterns. By week 12, your provider will assess your weight loss progress and determine whether your current dose is effective or needs adjustment. Clinical response is typically assessed at 12-16 weeks. If you have not experienced meaningful weight reduction by this point, your provider may discuss alternative approaches.

Yes. Light to moderate exercise is generally safe and beneficial during your first month. However, start gradually, especially if you experience fatigue or nausea. Focus on low-impact activities like walking, swimming, or gentle cycling. Resistance training 2-3 times per week is recommended to preserve lean muscle mass, which is important because GLP-1 medications can cause some lean mass loss along with fat loss. Listen to your body and avoid intense workouts if you feel unwell.

If you miss a dose and it has been less than 5 days since your scheduled dose, take it as soon as you remember, then continue with your regular weekly schedule. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day. Do not take two doses to make up for a missed one. If you miss multiple doses or are unsure, contact your provider for guidance. Consistency is important for optimal results.